DiaMedica is a biotechnology company engaged in the development of first-in-class treatments for diabetes. DM-199, the company’s lead compound, is a recombinant human protein for treating both Type 1 and Type 2 diabetes and their related complications. DiaMedica is also in the process of developing DM-204, the first therapeutic GPCR agonist monoclonal antibody for the treatment of Type 2 diabetes and cardiovascular disease. For more information, visit the company’s Web site at www.diamedica.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: